Picard Medical Faces Fraud Suit as Net Loss Widens to $27M

Edgen Stock

·Mar 31 2026, 06:22

Share to

Share to

Copy link

Key Takeaways

A securities fraud lawsuit targeting Picard Medical is moving forward, with an April 13, 2026, deadline for investors to seek lead plaintiff status. The legal action follows the company's full-year 2025 financial report, which revealed deepening losses and negative gross margins despite a public listing and rising revenue, raising questions about statements made during the class period.

Lawsuit Deadline: Investors who purchased PMI stock between September 2, 2025, and October 31, 2025, have until April 13, 2026, to file for lead plaintiff status in a securities fraud case.
Deteriorating Financials: Picard Medical's net loss expanded to $27.0 million in 2025, a 28% increase from the $21.1 million loss recorded in 2024.
Negative Margins: Despite revenue growing 12.5% to $4.94 million, the company's gross margin worsened from -2.6% to -4.1%, indicating it lost more money on its products year-over-year.

Picard Faces Lawsuit Over Alleged Misleading Statements

Investors in Picard Medical, Inc. (NYSE American: PMI) have until April 13, 2026, to apply for lead plaintiff status in a securities fraud lawsuit. The action, announced by Rosen Law Firm, covers individuals who purchased the company's securities between September 2, 2025, and October 31, 2025. A successful suit could entitle investors from this period to compensation. The lawsuit suggests that statements made by the company during this two-month window may have been materially misleading to the market.

2025 Financials Show Losses Deepening to $27 Million

Picard Medical's full-year 2025 financial results, released on March 25, 2026, paint a challenging financial picture that contrasts with its executive commentary. While total revenue increased 12.5% to $4.94 million, the company's net loss widened significantly to $27.0 million from $21.1 million in 2024. Furthermore, gross margin deteriorated to -4.1% from -2.6% the prior year, signaling that the company is spending more to generate sales of its SynCardia Total Artificial Heart. The company used $15.7 million in cash for its operations, relying on $27.1 million raised from financing activities to boost its cash reserves to $11.5 million.

Despite these figures, CEO Patrick NJ Schnegelsberg described 2025 as a "transformational year" marked by a public listing and revenue growth during a business update call on March 25, 2026. The company's own outlook confirms it will require additional capital to fund operations and product development, highlighting ongoing financial pressures. This disconnect between optimistic public statements and worsening core financial metrics likely forms the basis of the investor lawsuit.